Tag: GCP compliance

Case Studies: Interim Analyses That Stopped Trials Early—for Good or Bad

Posted on By digi

Case Studies: Interim Analyses That Stopped Trials Early—for Good or Bad Case Studies: Interim Analyses That Stopped Trials Early—for Good or Bad Interim analyses play a crucial role in the management and evaluation of clinical trials. By analyzing data at predetermined intervals, researchers can make informed decisions about the continuation or termination of a trial….

Read More “Case Studies: Interim Analyses That Stopped Trials Early—for Good or Bad” »

Interim Analyses & Alpha Spending

Categorizing and Prioritizing Issues for Timely Response

Posted on By digi

Categorizing and Prioritizing Issues for Timely Response Categorizing and Prioritizing Issues for Timely Response In the realm of clinical trials, particularly in til therapy clinical trials, efficient management and resolution of arising issues are critical to maintaining compliance and ensuring the successful progression of studies. This article serves as a comprehensive guide for clinical operations,…

Read More “Categorizing and Prioritizing Issues for Timely Response” »

Issue Management & Escalation Paths

Governance Forums to Review and Decide on Critical Issues

Posted on By digi

Governance Forums to Review and Decide on Critical Issues Understanding Governance Forums in Clinical Trials The governance structure of clinical trials is essential for ensuring adherence to regulatory requirements and maintaining trial integrity. Governance forums offer a collaborative framework for clinical operations, regulatory affairs, and medical affairs professionals to assess and address critical issues arising…

Read More “Governance Forums to Review and Decide on Critical Issues” »

Issue Management & Escalation Paths

Data Flow Mapping to Identify Integrity Risks Across the Study Ecosystem

Posted on By digi

Data Flow Mapping to Identify Integrity Risks Across the Study Ecosystem Data Flow Mapping to Identify Integrity Risks Across the Study Ecosystem Data integrity in clinical trials is critical to ensuring the validity and reliability of trial results. With increasing regulatory scrutiny and the imperative to maintain compliance with established standards such as ALCOA++ and…

Read More “Data Flow Mapping to Identify Integrity Risks Across the Study Ecosystem” »

Data Integrity (ALCOA++, 21 CFR Part 11)

Handling Corrections, Late Entries and Data Changes in GCP Systems

Posted on By digi

Handling Corrections, Late Entries and Data Changes in GCP Systems Handling Corrections, Late Entries and Data Changes in GCP Systems The integrity of data in clinical trials is paramount for regulatory compliance, particularly under the guidelines of ICH-GCP, 21 CFR Part 11, and various other regulations established by authorities such as FDA, EMA, and MHRA….

Read More “Handling Corrections, Late Entries and Data Changes in GCP Systems” »

Data Integrity (ALCOA++, 21 CFR Part 11)

Regulatory Expectations for Interim Analyses in Pivotal Programs

Posted on By digi

Regulatory Expectations for Interim Analyses in Pivotal Programs Regulatory Expectations for Interim Analyses in Pivotal Programs Conducting clinical trials is a complex process governed by multiple regulatory frameworks, especially when it comes to pivotal programs. Among the many components of clinical trial design, interim analyses stand out as critical milestones. This article aims to provide…

Read More “Regulatory Expectations for Interim Analyses in Pivotal Programs” »

Interim Analyses & Alpha Spending

Designing Escalation Paths for Site, Data and Vendor Issues

Posted on By digi

Designing Escalation Paths for Site, Data and Vendor Issues Designing Escalation Paths for Site, Data and Vendor Issues In the highly regulated field of clinical trials, effective issue management is paramount. Within clinical research organization companies, the process of identifying, escalating, and resolving issues is critical to ensuring trial integrity and compliance. This comprehensive guide…

Read More “Designing Escalation Paths for Site, Data and Vendor Issues” »

Issue Management & Escalation Paths

Integrated Issue Management Across CTMS, eTMF and Quality Systems

Posted on By digi

Integrated Issue Management Across CTMS, eTMF and Quality Systems Integrated Issue Management Across CTMS, eTMF and Quality Systems Integrated issue management is critical for the success of clinical trials, particularly in the evolving landscape of biosimilar clinical trials, til therapy clinical trials, and others like the donanemab clinical trial or Sanofi clinical trials. This tutorial…

Read More “Integrated Issue Management Across CTMS, eTMF and Quality Systems” »

Issue Management & Escalation Paths

Designing Systems and Processes That Embed ALCOA++ Principles

Posted on By digi

Designing Systems and Processes That Embed ALCOA++ Principles In an era where data integrity is paramount in clinical research, the principles of ALCOA++ are essential in ensuring the quality and reliability of clinical trial data. This step-by-step guide will provide clinical operations, regulatory affairs, and medical affairs professionals in the US, UK, and EU with…

Read More “Designing Systems and Processes That Embed ALCOA++ Principles” »

Data Integrity (ALCOA++, 21 CFR Part 11)

Part 11 Requirements for Electronic Records, Signatures and Audit Trails

Posted on By digi

Part 11 Requirements for Electronic Records, Signatures and Audit Trails Understanding Part 11 Requirements for Electronic Records, Signatures and Audit Trails The advent of electronic records in clinical trials has revolutionized data management. However, it also introduces regulatory challenges that professionals must navigate to ensure compliance with international standards. This guide will provide a comprehensive…

Read More “Part 11 Requirements for Electronic Records, Signatures and Audit Trails” »

Data Integrity (ALCOA++, 21 CFR Part 11)